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Background: The relationship between antibiotic use and the incidence of triazole-
resistant phenotypes of invasive candidiasis (IC) in critically ill patients is unclear.
Different methodologies on determining this relationship may yield different results.
Methods: A retrospectivemulticenter observational analysis was conducted to investigate
exposure to antibiotics and the incidence of non-duplicate clinical isolates of Candida spp.
resistant to fluconazole, voriconazole, or both during November 2013 to April 2018, using
two different methodologies: group-level (time-series analysis) and individual-patient-level
(regression analysis and propensity-score adjusting).
Results: Of 393 identified Candida spp. from 388 critically ill patients, there were three
phenotypes of IC identified: fluconazole-resistance (FR, 63, 16.0%); voriconazole-resistance
(VR, 46, 11.7%); and cross-resistance between fluconazole and voriconazole (CR, 32, 8.1%).
Exposure to several antibacterial agents with activity against the anaerobic gastrointestinal
flora, especially third-generation cefalosporins (mainly cefoperazone/sulbactam and
ceftriaxone), but not triazoles, have an immediate effect (time lag  0) on subsequent ICU-
acquired triazole-resistant IC in the group-level (p < 0.05). When the same patient database
was analyzed at the individual-patient-level, we found that exposure to many antifungal agents
was significantly associated with triazole-resistance (fluconazole [adjusted odds ratio (aOR) 
2.73] or caspofungin [aOR  11.32] on FR, voriconazole [aOR  2.87] on CR). Compared to
the mono-triazole-resistant phenotype, CR IC has worse clinical outcomes (14-days mortality)
and a higher level of resistance.
Conclusion: Group-level and individual-patient-level analyses of antibiotic-use-versus-
resistance relations yielded distinct but valuable results. Antibacterials with antianaerobic
activity and antifungals might have “indirect” and “direct” effect on triazole-resistant IC,
respectively.
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INTRODUCTION
Invasive candidiasis includes both bloodstream and deep-seated
invasive infections caused by Candida species (Martin-Loeches
et al., 2019). Candida spp. account for up to 17% of all intensive-
care unit (ICU)-acquired infections globally (Vincent et al., 2009).
Half of candidemia episodes occur in the ICU setting reflecting the
complexity of illness usually associated with this infection (Pappas
et al., 2018). The incidence and mortality rates for IC in ICU
patients have progressively increased over time (Lortholary et al.,
2014); a mortality rate approaching 40% has been reported for
ICU-acquired IC in most series (Calandra et al., 2016).
Echinocandins and triazoles (mainly fluconazole and
voriconazole) are backbones for the treatment of IC and are
recommended by several guidelines (Wang et al., 2019).
Although echinocandins are increasingly regarded as first-line
treatment superior to fluconazole, the echinocandin-resistant rate
remains relatively low (Perlin, 2015). Triazoles are still the most
wildly used antifungal agents worldwide (Guo et al., 2013;
Vallabhaneni et al., 2018). Given that antifungal resistance is an
emerging threat to the initiation of appropriate antifungal treatment,
early recognition of risk factors for patients who may experience
triazole-resistant IC can improve patient survival (Perlin et al., 2017).
Previous studies demonstrated that exposure to antibiotics, (i.e.
antifungal or antibacterial agents) is a prominent factor for
increasing the risk of emergence and resistance of Candida
species (Ben-Ami et al., 2012; Martin-Loeches et al., 2014;
Jensen et al., 2015). However, most of these studies were based
on data from individual-patients and it is known that antimicrobial
treatment may exert effects on individual-patients that are
substantially different in magnitude to the effects at the
population-level, (i.e. group-level) (Lipsitch and Samore, 2002).
For many types of pathogens, the relationship between antibiotic
usage and resistance is mediated by selection at the population-
level due to patient-to-patient transmission; it also applies to
Candida spp. in ICU (Hammarskjold et al., 2013). Therefore,
adopting the perspective of both the group and individual-
patient level to identify the relationship between antibiotic usage
and triazole-resistant IC will inform therapeutic decision making.
The objectives of this study were to: 1) model the time-varying
effect of antibiotic use, (i.e. antifungals and antibacterials; aggregated
data) on the incidence of three triazole-resistant phenotypes
(fluconazole-resistance [FR], voriconazole-resistance [VR], and
cross-resistance between voriconazole and fluconazole [CR]) in
ICU patients using autoregressive integrated moving average
(ARIMA) models and a transfer function, (i.e. group-level); 2)
perform individual-patient-level analyses to identify potential
antibiotic-risk factors associated with the three resistant
phenotypes by using the same dataset, comparing the similarities
and differences of the results from two different methodologies.
MATERIALS AND METHODS
Study Design and Patients
This retrospective study was performed at two urban, tertiary
hospitals (2,700-bed and 2,200-bed, respectively), affiliated with the
same university. These are the two largest tertiary hospitals in the area
of central and south of Xi’an, and adopt similar medical models and
practice guidelines. The ICUs of these two hospitals have 100 and 50
beds, respectively. The data collection procedures were approved by
each hospital’s institutional review board. All data in this study were
collected retrospectively, all patient data were anonymous and all
laboratory information were part of routine testing, so informed
consent was waived (No. 2015-XJTUFAH-002 and No.
XJTUSAH-2020071).
Adult patients (age ≥18 years) were enrolled if diagnosed with
proven IC in ICU and ICU stay ≥3 days. Proven IC was defined as
a clinical illness consistent with an IC diagnosis combined with a
Candida spp. isolate being detected by positive specimen culture
taken from a sterile site (tissue or blood) or through
histopathological evidence.
The four exclusion criteria were: 1) patients with neutropenia
(absolute neutrophil count <500 cells/μl), hematologic malignancy, or
after hematopoietic stem cell transplant; 2) microbiological isolates
collected within 48 h of ICU admission; 3) being infected with rare
Candida species whose clinical breakpoints or epidemiological cutoff-
values for fluconazole and voriconazole have not been determined;
and 4) incomplete data on susceptibility testing.
The details of antibiotic use, Candida spp. identification and
susceptibility testing, and individual-patient data collection are
provided in the (Supplementary Appendix SA1).
Statistical Analysis
Group-Level Analysis
We determined if there were significant changes in monthly
antibiotic use, the incidence of the most commonly isolated
Candida spp., and the triazole-resistant Candida spp., (i.e. FR, VR
and CR) using linear regression over the study period. Application of
simple regression analyses would be inappropriate as the temporally
sequenced observations on antibiotic use, the incidence of Candida
spp., and the resistance isolates are not independent (Lopez-Lozano
et al., 2000). Therefore, we assessed the relationship betweenmonthly
antibiotic use and monthly incidence of triazole-resistant Candida
spp.; as well as monthly incidence of Candida spp. using a dynamic
regression model. In the current study, this method comprises
modeling the monthly incidence of Candida spp. or triazole-
resistant Candida spp (explained variable) using ARIMA models
with the Box–Jenkins method, integrating the stochastic dependence
of consecutive data over time (Helfenstein, 1996). Then, the transfer
function (TF) modeling method was employed to quantify the
dynamic relationship by adding antibiotic use as an explanatory
variable, and the possible time delays (lags) of up to six months was
considered (Lopez-Lozano et al., 2000; Vernaz et al., 2011). This
methodology has been proposed by Lopez-Lozano et al. as a suitable
method to examine the relationship between antibiotic exposure and
the emergence of drug-resistance (Lopez-Lozano et al., 2000) (See
details of the statistical analysis of ARIMA and TF model in the
Supplementary Appendix SA2).
Individual-Patient-Level Analysis
A multivariate multinomial regression analysis was performed to
identify risk factors for IC due to non-albicans Candida species,
using C. albicans as reference.
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A multivariate stepwise logistic regression model with
backward selection was used to determine the relevant factors
of FR, VR and CR. A p < 0.05 was considered statistically
significant in the final multivariate model. To limit
confounding by nonantibiotic-risk factors, we calculated the
conditional probability of recent exposure to specific antibiotics
based on nonantibiotic-risk factors using propensity-score
adjusting analysis. We estimated the cumulative incidence of
14 days all-cause mortality by using the Kaplan-Meier product-
limit method. The difference in cumulative incidence was
compared by the log-rank test for trend and Cox regression
analysis (see details of the statistical analysis of the regression
model in the Supplementary Appendix SA3). All statistical
analyses were performed using SAS 9.4 (SAS Inc.).
RESULTS
We identified 393 episodes of IC in 388 patients during the
54months study period. Of these episodes, the median age was
63 years (IQR 46, 74 years) and, 221 (56%) patients weremale. There
were amedian of 119 (IQR 109, 130) ICU discharges per month and
the median duration of ICU stay was 11.38 days (IQR 9.74, 13.42).
Antibiotic Use and Triazole-Resistance of
Candida spp
Detailed antibiotic use and Candida spp. results are presented in
the Supplementary Material (Supplementary Appendix SA4).
Trends in the use of each class of antibiotics are summarized in
the Supplementary Table S1 (Supplementary Appendix SA5).
The distribution and the incidence of triazole-resistance of
Candida spp. are shown in Table 1.
The number of species associated with a high fluconazole MIC
(≥64 μg/ml) related to CR Candida infections (16/32, 50.0%) was
higher than that of mono-resistanceCandida infections (5/31, 16.1%,
p  0.004), and a non-significant trend for high MIC (≥2 μg/ml) of
voriconazole (16/32 [50.0%] vs. 3/14 [21.4%], respectively, p 0.070).
Group-Level Analysis
The results of correlations between antibiotic use and Candida spp.
distribution were presented in the Supplementary Material
(Supplementary Appendixes SA6, SA7; Supplementary Table S2).
There were positive relationships between the incidence of FR
IC and several potential explanatory variables in the dynamic
regression model; for third-generation cefalosporins (mainly
cefoperazone/sulbactam and ceftriaxone), first-generation
cefalosporins, and linezolid. Temporal variations in third-
generation cefalosporins use were followed by variations in FR
IC incidence immediately, (i.e. no delay). After the third-
generation cefalosporins usage increase (or decrease) by one
DDD/100PD, the incidence of FR IC immediately increase (or
decrease) by 0.0016/100PD. The variation of FR IC incidence was
0.083/100PD for first-generation cefalosporin (3 months delay)
and 0.011/100PD for linezolid (2 months delay) (Table 2 and
Figure 1A). Over the study period, half (52%) of the variations of
the monthly incidence of FR IC were explained by the factors
included in the model (R2 0.52).
The incidence of VR IC was positively correlated with the
previous use of third-generation cefalosporins and first-generation
cefalosporins. The variation of VR was 0.0016/100PD for third-
generation cefalosporins and 0.029/100PD for first-generation
TABLE 1 | Episodes of invasive candidiasis in number and incidence (per 100 patient-days) of non-duplicate Candida spp. distribution and resistance to fluconazole and









C. albicans No. (%) of isolate 5 (45.5) 42 (55.3) 65 (67.7) 81 (71.7) 52 (63.4) 4 (26.7) 249 (63.4)
Incidence 0.23 0.32 0.46 0.57 0.32 0.08 0.612
C. glabrata No. (%) of isolate 3 (27.3) 10 (13.2) 16 (16.7) 10 (8.8) 7 (8.5) 3 (20.0) 49 (12.5)
Incidence 0.14 0.08 0.11 0.07 0.04 0.06 0.157
C. tropicalis No. (%) of isolate 2 (18.2) 13 (17.1) 5 (5.2) 11 (9.7) 13 (15.9) 3 (20.0) 47 (12.0)
Incidence 0.09 0.10 0.04 0.08 0.08 0.06 0.930
C. parapsilosis No. (%) of isolate 1 (9.1) 0 (0) 3 (3.1) 2 (1.8) 5 (6.1) 2 (13.3) 13 (3.3)
Incidence 0.05 0 0.02 0.01 0.03 0.04 0.133
C. krusei No. (%) of isolate 0 (0) 4 (5.3) 2 (2.1) 3 (2.7) 2 (2.4) 2 (13.3) 13 (3.3)
Incidence 0 0.03 0.01 0.02 0.01 0.04 0.688
Other Candida spp. No. (%) of isolate 0 (0) 7 (9.2) 5 (5.2) 6 (5.3) 3 (3.7) 1 (6.7) 22 (5.6)
Incidence 0 0.05 0.04 0.04 0.02 0.02 0.430
All Candida spp. No. (%) of isolate 11 (100) 76 (100) 96 (100) 113 (100) 82 (100) 15 (100) 393
Incidence 0.51 0.57 0.67 0.80 0.50 0.29 0.384
Antifungal resistance to
Fluconazole No. (%) of isolate 3 (27.3) 15 (19.7) 14 (14.6) 19 (16.8) 8 (9.8) 4 (26.7) 63 (15.9)
Incidence 0.14 0.11 0.10 0.13 0.05 0.08 0.126
Voriconazole No. (%) of isolate 1 (9.1) 16 (21.1) 10 (10.4) 13 (11.5) 4 (4.9) 2 (13.3) 46 (11.6)
Incidence 0.05 0.12 0.07 0.09 0.02 0.04 0.009
Cross-resistance No. (%) of isolate 0 (0) 10 (13.2) 5 (5.2) 12 (10.6) 4 (4.9) 1 (6.7) 32 (8.1)
Incidence 0 0.08 0.04 0.08 0.02 0.02 0.243
ap values are generated by linear regression.
Frontiers in Pharmacology | www.frontiersin.org March 2021 | Volume 12 | Article 5868933
Wang et al. Triazole-Resistant IC in ICU Patients
cefalosporins (both for no delay) (R2 0.42, Table 2 and Figure 1B).
For CR IC, the incidence of CR IC was positively correlated with
previous use of third-generation cefalosporins (0.0009/100PD, no
delay) and benzylpenicillin (0.022/100PD, average delay of one
month; R2 0.30, Table 2 and Figure 1C).
Individual-Patient-Level Analysis
The results of multinomial regression analysis for different Candida
species were presented in the Supplementary Material
(Supplementary Appendixes SA6, SA8; Supplementary Table S3).
The demographic and clinical characteristics of the study
patients (n  393) and patients with different triazole-resistant
phenotypes, as well as some associations for FR, VR, and CR IC
identified in the bivariate analysis are presented in the
Supplementary Table S4; Supplementary Appendix SA9).
The independent antibiotic-risk factors for FR IC included
previous exposure to fluconazole (odds ratio [OR] 2.73, 95%
confidence interval [CI] 1.38, 5.39, p  0.004), caspofungin (OR
11.32, 95% CI 2.48, 51.74, p  0.002), or glycopeptides (mainly
vancomycin) (OR 2.32, 95% CI 1.22, 4.42, p  0.010; Table 3). We
found no associations with VR IC after adjusted for propensity-
scores (Table 3). CR IC was positively associated with previous
exposure to voriconazole only (OR 2.87, 95%CI 1.03, 8.01, p 
0.045) (Table 3). After adjusting for propensity-scores and SOFA
score, exposure to fluconazole was associated with a non-statistically
significant trend for CR IC (OR 2.26, 95%CI 0.96, 5.30, p  0.062).
Clinical Outcomes
The 14 days all-cause mortality rate was 26.0% (101/388) among
the ICU patients. The rate varied: CR IC was 43.8% (14/32),
mono-triazole-resistant IC was 26.7% (12/45) while those with
non-resistant IC was 24.1% (75/311, p  0.006; Figure 2). There
was an association between 14 days all-cause mortality and
resistant phenotypes (adjusted hazards ratio [aHR] 1.55, 95%
CI 1.17, 2.05, p  0.002) after adjusting for APACHE II scores at
IC diagnosis (aHR 1.08, 95%CI 1.05, 1.11, p < 0.001), and invasive
mechanical ventilation (aHR 1.80, 95%CI 1.10, 2.95, p  0.021).
There was no difference in the length of stay following infection
between patients with FR IC and patients with non-FR IC,
between patients with VR IC and patients with non-VR IC,
nor between patients with CR IC and patients with non-CR
IC (Supplementary Table S4; Supplementary Appendix SA9).
DISCUSSION
Exposure to antibiotic remains one of the most important risk
factors for acquiring antibiotic-resistant Candida spp. (Ben-Ami
et al., 2012). We applied two different methodologies (group-level
and individual-patient-level) to analyze antibiotic-use-versus-
resistance relations for Candida spp. isolates in critically ill
patients, yielding distinct results. Exposure to several
antibacterial agents, specifically third-generation cefalosporins,
but not triazoles, have an immediate effect (time lag  0) on
subsequent ICU-acquired triazole-resistant IC in the group-level,
indicating an "indirect" effect on resistance. When the same
patient database was analyzed at the individual-patient-level,
we found that exposure to many antifungal agents was
significantly associated with triazole-resistance.
In group-level analyses, previous fluconazole use (for 3-
months delay) was associated with the emergence of FR, VR
and CR IC when using univariate TF models. However, when we
introduced third-generation cefalosporins exposure (mainly
cefoperazone/sulbactam and ceftriaxone) into the multivariate
TFmodel, exposure to fluconazole was no longer a significant risk
factor for developing triazole-resistant IC and the model
performance became better to predict the real incidence of
resistant isolates. The antibiotic-associated collateral damage
which implies certain antibacterials with an antianaerobic
spectrum of activity promote subsequent infection with C.
glabrata infection (potentially resistant) (Lin et al., 2005) or
FR infection (Ben-Ami et al., 2012) has been noted. Candida
species coexists with a vast number of bacterial species in the
human gastrointestinal tract, most of which are facultative or
TABLE 2 | Antibiotic use for the incidence (per 100 patient-days) of non-duplicate Candida spp. resistant to azoles (November 2013 to April 2018) using a multivariate
transfer function model.
Variable Lag (months) Parameter (95% confidence
interval)
T Statistic P valuea
Fluconazole-resistance (R2  0.52)
Third-generation cefalosporins 0 0.0016 (0.0011,0.0021) 6.71 <0.001
First-generation cefalosporins 3 0.083 (0.051, 0.114) 5.14 <0.001
Linezolid 2 0.011 (0.003, 0.020) 2.70 0.007
Autoregressive term 5 −0.293 (−0.574, -0.013) −2.05 0.041
Voriconazole-resistance (R2  0.42)
Third-generation cefalosporins 0 0.0016 (0.0011, 0.0020) 7.12 <0.001
First-generation cefalosporins 0 0.029 (0.006, 0.052) 2.43 0.015
Moving average term 1 −0.323 (−0.609, −0.036) −2.21 0.027
2 0.331 (0.046, 0.616) 2.28 0.023
Cross-resistance (R2  0.30)
Third-generation cefalosporins 0 0.0009 (0.0006, 0.0012) 6.33 <0.001
Benzylpenicillin 1 0.022 (0.009, 0.035) 3.41 <0.001
Moving average term 2 0.394 (0.135, 0.653) 2.98 0.003
ap values are generated by multivariate transfer function model.
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obligatory anaerobes. Most IC are caused by translocation from
endogenous reservoir to normally sterile body sites. Cefoperazone/
sulbactam, ceftriaxone, linezolid and benzylpenicillin, which were
identified by group-level analyses for triazole-resistant IC, all have
certain anti-anaerobic activity. The probable mechanism is that
these antibiotics significantly alter the balance of different
components of the indigenous microbial flora, which may
persist for months after a relatively short course of treatment
(Dethlefsen and Relman, 2011). Simply by killing off competing
flora of different species, treatment with one agent may increase the
FIGURE 1 | Monthly incidence of non-duplicate triazole-resistant isolates and antibiotic consumption per 100 patient-days (A) Fluconazole-resistant invasive
candidiasis (B) Voriconazole-resistant invasive candidiasis (C) Cross-resistant invasive candidiasis. The number on the x-axis are months (from November 2013 to April 2018).
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burden of a pathogen resistant to another agent. For example, this
has been observed with anti-anaerobic treatments that increase the
load of vancomycin-resistant Enterococci (Donskey et al., 2000), as
well as ceftriaxone, piperacillin-tazobactam, and metronidazole
treatments that promote Candida glabrata colonization in the
feces of mice (Pultz et al., 2005). Other proposed mechanisms
include direct antifungal activities or modulating azole resistance
by inducing the expression of efflux-pump-encoding genes of some
antibacterials (de Micheli et al., 2002; Zhai et al., 2010).
Regarding the patient-level analyses, previous exposure to
fluconazole or caspofungin was positively correlated with the
emergence of FR IC. Given that previous exposure to
echinocandins is a significant risk factor for echinocandin-
resistance and multidrug resistance, our results might suggest
echinocandin-resistance was strongly associated with FR, which
is in agreement with previous reports (Farmakiotis et al., 2014;
Pham et al., 2014). We only found that exposure to fluconazole
can affect FR, but not VR and CR, while exposure to voriconazole
would affect CR, but not VR. These findings were in accord with
another report (Bailly et al., 2016), suggesting that we should use
voriconazole carefully to avoid causing more serious drug-
resistance. No triazole affected VR IC: this was unexpected
and needs to be confirmed by further studies.
Particularly important findings of this study were the all-cause
mortality were closely related to different resistant phenotypes (CR vs.
mono-triazole-resistance vs. non-resistance) after adjusting for severity
of illness, and the number of species associated with high fluconazole
or voriconazole MIC was greater for CR IC than for mono-triazole-
resistant IC, indicating a higher level of resistance for CR species.
Altogether, CR IC may have a worrisome propensity compared to
mono-triazole-resistant IC. Nevertheless, the new Chinese medical
insurance policy 2020 may still force Chinese clinicians to prioritize
triazoles (mainly fluconazole and voriconazole), despite investigations
showing that initial echinocandin treatment reduces mortality in
critically ill patients with candidemia (Garnacho-Montero et al.,
2018). This paradoxical dilemma might lead to therapeutic failure
and decrease the survival of patients with IC.
Different types of epidemiological studies have been
performed to quantify the association between antibiotic
exposure and Candida resistance (Ben-Ami et al., 2012;
Farmakiotis et al., 2014; Bailly et al., 2016). Our results
indicated the different methodological approaches are not
mutually transposable. Some experts indicated that group-level
analytic methods alone cannot reliably clarify causal relationships
between exposure to antibiotic and resistance due to some
ecological biases, (e.g. the key information was lost in the data
aggregation process-the sequence of antibiotic exposure and the
emergence of a resistant organism has not been reflected).
However, ecological studies (aggregated data) are potentially
helpful for the researches of infectious diseases, since they can
estimate the overall effect of antibiotic exposure, (i.e. not just the
direct effects on the individual receiving the antibiotic but also the
TABLE 3 | Adjusted odds of antibiotics associated with fluconazole-resistant, voriconazole-resistant and cross-resistant invasive candidiasis using multivariate analyses.
Characteristic Fluconazole-resistance Voriconazole-resistance Cross-resistance
Adjusted OR (95% CI)c p Valuea Adjusted OR (95% CI) p Valuea Adjusted OR (95% CI)d p Valueb
Exposure to fluconazole 2.73 (1.38, 5.39) 0.004 – – 2.26 (0.96, 5.30) 0.062
Exposure to caspofungin 11.32 (2.48, 51.74) 0.002 – – – –
Exposure to glycopeptides (mainly vancomycin) 2.32 (1.22, 4.42) 0.010 – – – –
Exposure to voriconazole – – – – 2.87 (1.03, 8.01) 0.045
OR: Odds Ratio; CI: Confidence Interval; SOFA: Sequential Organ Failure Assessment.
aGenerated by multivariate regression analysis adjusted for antibiotic-related propensity score (p  0.781).
bGenerated by multivariate regression analysis adjusted for antibiotic-related propensity score (p  0.350) and SOFA score (p  0.035).
cHosmer-Lemeshow test 64.42, p  0.532.
dHosmer-Lemeshow test 81.25, p  0.994.
FIGURE 2 | Cumulative survival in patients with cross-resistant, mono-triazole-resistant, and non-resistant invasive candidiasis using Kaplan-Meier
curves. The dashed line indicates the 95% confidence interval: yellow for non-resistant; green for mono-triazole-resistant; red for cross-resistant invasive candidiasis.
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indirect effects mediated through effects on transmission
capacity). (Harbarth et al., 2001). Therefore, considering the
different ways in which antibiotics affect antimicrobial
resistance, antibacterials with antianaerobic activity seem to
have an “indirect” effect, while antifungal agents have a
“direct” effect on triazole-resistant IC.
We acknowledge five limitations of our study. Firstly, this is
a retrospective analysis and our sample size was relatively small
for differentiating individual resistant Candida species.
Inherent risk factors may differ between single species and
the combined ones we used but several studies examining
potential factors for resistance also treated multiple species
as a single group. Secondly, the antifungal agents tested in the
present study were limited to only two triazoles so multidrug
resistance among different antifungal classes could not be
assessed. Multidrug-resistant Candida species are not
uncommon—a third (36%) of echinocandin-resistant isolates
were also resistant to fluconazole (Pham et al., 2014). Thirdly,
both the ARIMA or regression models could have missed
several confounding factors, which might bias the results
and lead to the observed relationships. Additionally, the
stepwise regression analysis does not always choose the best
possible combination of risk factors. When there is a small
sample size compared to the number of variables being studied,
the selection of variables using a stepwise regression will be
unstable. Nevertheless, this instability is reduced when there is
a sample size (or number of events) greater than 50 per
candidate variable (Steyerberg et al., 2001). Moreover, by
reducing the number of variables, stepwise selection will
yield a simple and easily interpretable model. Fourthly, we
adopted incidence as our measure for the burden of IC. It is
noted that measuring the proportion of resistant isolates among
all isolates is a common method, especially for situation where
the overall number of infections does not change dramatically
(Burton et al., 2009; Schechner et al., 2013). Nevertheless, the
use of antibiotics will reduce the number of susceptible isolates,
so even if the number of resistant isolates does not increase, the
proportion of resistant organisms would increase. Schechner
and colleagues, therefore instead recommend the “incidence”
as an indicator of the burden of resistance (Schechner et al.,
2013). Finally, the resistance mechanism of triazoles and
defining genotype relationships between the species by
molecular typing have not been clarified in our study. The
clarification of these mechanisms can better help understand
the level of resistance to triazoles and confirm the patient-to-
patient transmission.
Despite these limitations, we believe that this study is valuable
since it combines two different statistical methods (group-level
and individual-patient-level) to provide further evidence on how
antibiotic use influences the incidence of varying triazole-
resistance in ICU patients, which allows us to interpret the
results in two divergent perspectives. Moreover, we were able
to investigate clinical outcomes for different resistant phenotypes
to confirm the worrying status of antifungal resistance.
In conclusion, antibacterials with antianaerobic activity and
antifungals might have “indirect” and “direct” effect on
triazole-resistant IC, respectively, suggesting that preventing
the misuse of antifungals and antibacterials with activity against
the anaerobic gastrointestinal flora in ICU is necessary to avoid
triazole-resistance phenomena without compromising the
efficacy of antifungal therapy. Inappropriate initial treatment
might lead to the more-complicated and worse cross-resistant
phenotype, which should be considered when formulating
healthcare policies.
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